Clinical capabilities iCura Diagnostics operates as a CLIA High Complexity-certified, CAP-accredited CRO and clinical diagnostic lab with expertise in spatial biology, tumor micro-environment mapping, multiplex immunofluorescence, IHC, digital pathology, dPCR/qPCR, and NGS, presenting multiple high-value service lines for translational research and biomarker development.

End-to-end support The company offers end-to-end services from method development and validation through sample testing, regulatory compliance, and clinical trial logistics, enabling faster onboarding for sponsors seeking integrated pathology and biomarker workflows.

Covid-19 diagnostic activity Recent news highlights ongoing development of Covid-19 diagnostic kits, signaling expansion into rapid, accessible infectious disease testing which could open additional collaboration opportunities and diversify project portfolios.

Strategic collaborations With a focus on collaborating across the drug development pipeline and leveraging advanced tissue pathology analytics, iCura can partner on predictive biomarker discovery, patient stratification, and target identification for oncology and related translational programs.

Growth signals Current revenue range (10 to 25 million USD) and a small team size suggest a nimble CRO partner with potential for retainer-based projects, faster decision cycles, and scalable service packages appealing to mid-to-large biotech firms seeking specialized spatial biology capabilities.